Maberry, Mackenzie

Objective: To gain firsthand accounts from female physician leaders in academic medicine to better understand the challenges and success factors they have encountered in order to provide insights to early-career female physicians and inform organizations about the challenges faced by female physicians to build better systems and processes to support them in achieving more satisfying and fulfilling careers within an academic setting. Method: This qualitative research study is based on interviews with female physician leaders. Participants were selected based on their scores in multi-rater leadership assessments taken within the past three years, all ranking in the top 30% across four capabilities: Inspiring Values, Engaging Colleagues, Bold and Forward Thinking, and Driving Results. Coding and thematic analysis were used to categorize the challenges and success factors. Results: Data analysis revealed challenges experienced by these female physician leaders, including gender bias, time constraints, family responsibilities, change and innovation, self-doubt, and exclusion from networking. The strategies identified for navigating these challenges and achieving high performance included support from family and colleagues, building relationships and networking, maintaining a positive attitude, making powerful choices, seizing opportunities, finding value, meaning, and purpose, continuous learning, strategic planning, and gaining recognition. Conclusion: Challenges for female leaders in academic medicine are prevalent and evolve alongside changes in health care. Success factors can be generated at an individual level, such as attitudes, making powerful choices, and networking. However, societal and organizational support, including assistance with family responsibilities and providing opportunities, feedback, and mentorship, has also been identified as crucial.

Background Cirrhosis is associated with significant healthcare utilization, yet data about in-hospital decompensations remain sparse. Additionally, the impact of liver transplant candidacy status on resuscitation and outcomes is largely unknown. Aims We aimed to evaluate the characteristics of resuscitation events for patients with cirrhosis with acute decompensation, analyzing liver transplant candidacy and intensive care unit (ICU) transfer parameters. Methods Retrospective single-center review of adult patients with liver cirrhosis who had a rapid response team (RRT) activation during hospitalization and no prior liver transplantation. Results Patients with cirrhosis who were liver transplant candidates were more likely to be younger ( p = .003), have a higher serum total bilirubin ( p = .015), higher INR ( p < .001), and higher MELD 3.0 ( p = .006). There was no significant difference in ICU transfer ( p = .170) after RRT activation. Liver transplant candidates had a lower 30- and 60-day mortality ( p = .008, p = .014) and were less likely to have a code status discussion after decompensation ( p = .001). Lower serum albumin was associated with ICU transfer ( p = .001). Patients who transferred to the ICU were more likely to have a code status discussion within 24 h after RRT ( p = .011) without significant difference in 30- or 60-day mortality ( p = .059, p = .277). Conclusions Liver transplant candidacy in patients with cirrhosis with acute decompensation is not clearly correlated with ICU transfer. Liver transplant candidates are more likely to be younger, have higher MELD 3.0 scores, less likely to have code status discussed after RRT, and have lower 30- and 60-day mortality rates. Patients who transfer to the ICU are more likely to have a code status discussion without any significant difference in 30- or 60-day mortality.

Background Screening for monoclonal gammopathy (MG) is often performed in the evaluation of anemia. While certain MGs may be associated with anemia, these are rare conditions. Monoclonal gammopathy of undetermined significance (MGUS; prevalence of 8% among age &gt;50 years) is common, but rarely causes anemia in isolation. Therefore, abnormal results from MG screening may be unrelated to patient symptoms and result in both financial and psychological harm. Limited data exist to guide clinicians regarding the utility of MG testing for anemia. Aims This study aims to describe both the clinical utility of MG screening during the evaluation of anemia and the most common etiologies for anemia in patients whose workup included MG screening. Methods We reviewed medical records of patients who received MG screening to evaluate anemia at Mayo Clinic in 2021. Patients with a previously diagnosed MG were excluded. MG testing included serum protein electrophoresis and free light chain assessments. The following data were extracted: hemoglobin, hematocrit, mean corpuscular volume (MCV), calcium, creatinine, eGFR, and the final hematologic diagnosis related to the monoclonal protein. Clinician documentation was evaluated to determine the attributed etiology of anemia. Results Among the 271 patients with anemia who were screened for MG, 33 (12.2%) were found to have a newly diagnosed MG. Only 2 patients screened for MG were ultimately found to have anemia caused by MG. These included a case of multiple myeloma and one patient with cold agglutinin disease and secondary hemolysis. In all patients screened, their anemia was ultimately thought to be due to iron deficiency (31.7%), B12 deficiency (3.0%), anemia of chronic disease (ACD)/inflammatory anemia (14.4%), chronic kidney disease (CKD) (3.7%), hemolysis (1.5%), hypogonadism (1.9%), idiopathic (21.0%), multifactorial: iron deficiency + ACD/inflammatory (3.0%), multifactorial: nutritional; iron deficiency + B12 deficiency (3.0%), multifactorial: ACD + CKD (5.2%), multifactorial: iron deficiency + CKD (1.8%), multifactorial: not otherwise specified (NOS) (6.6%), medications (0.4%), and other (2.6%). Both patients with newly diagnosed MG associated anemia presented with peripheral neuropathy as their primary symptom. Among these 2 patients diagnosed with dysproteinemia associated anemia, only one (0.4%) was placed on therapy for their MG. Summary/Conclusions In the evaluation of anemia, routine MG screening has low clinical utility. Less than 1 in 100 patients were found to have anemia attributable to MG. Furthermore, only 0.4 in 100 patients received MG-directed therapy. Most patients screened with SPEP for undifferentiated anemia were found to have anemia attributable to common causes including iron/nutritional deficiency, inflammatory processes, and CKD. Most patients with undifferentiated anemia would benefit from an anemia evaluation that focuses on the most common causes up front. Given the cost to healthcare and potential psychological harm to the patient of incidental MG diagnosis, further study is warranted to guide clinicians and limit the ordering of MG testing to individuals who are most likely to derive benefit.